KIRSTY (water) by Biocon is insulin, including insulin aspart products, is the regulation of glucose metabolism. Approved for glycemic control in adults. First approved in 2025.
Drug data last refreshed 1h ago · AI intelligence enriched 2mo ago
KIRSTY is a novel insulin aspart analog injection approved by the FDA for glycemic control in adults with diabetes. It works by stimulating peripheral glucose uptake in skeletal muscle and fat while inhibiting hepatic glucose production, thereby lowering blood glucose levels. The drug also inhibits lipolysis and proteolysis while enhancing protein synthesis.
Early-stage launch with moderate competitive pressure (30%) presents opportunity for aggressive market penetration and team expansion within the first 24 months.
insulin, including insulin aspart products, is the regulation of glucose metabolism. Insulin and its analogs lower blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulin inhibits lipolysis and proteolysis,…
Insulin Analog
A Research Study Looking at the Effect of Timing of Meal After Dosing and Water Volume at Dosing on How the Medicine Zenagamtide is Taken up by the Body of Participants With Overweight or Obesity
Wastewater Surveillance for Carbapenem-Resistant Organism Outbreak Prediction in a Chinese Tertiary Hospital
Rural Water Filtration and Health Study
WATER IV PCa (AS Sub-study)
Water Vapor Ablation for Grade Group 3 Prostate Cancer
Worked on KIRSTY at Biocon? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moKIRSTY represents a launch-phase opportunity in a mature insulin category with significant commercial execution challenges and competitive intensity. Career roles will center on rapid market penetration, payer negotiation, and defending against imminent generic competition from competitor LOE transitions.